<DOC>
	<DOC>NCT00601315</DOC>
	<brief_summary>The objective of this study was the bioequivalence of a potential generic 250 mg clarithromycin tablet formulation compared with Abbott Laboratories 250 mg clarithromycin tablet, BiaxinÂ® following a single 250 mg dose, administered in the fasted state.</brief_summary>
	<brief_title>Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to clarithromycin or any other macrolide antibiotic.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>